Search Results 451-460 of 14945 for alt

1. A Phase 2 Trial Of ALN-APP In Patients With Cerebral Amyloid Angiopathy - Mayo Clinic

   * Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>3×upper limit of normal (ULN) at Screening * Has estimated glomerular filtration ...

2. Clinical Trials - A Study of Outpatients with Cirrhosis

   Platelet count < 150,000 and AST/ALT ratio > 1. Able and willing to provide samples. Specific additional inclusion criteria for the three subgroups ...

3. A Phase Ⅲ Study Of Rilvegostomig In Combination With Fluoropyrimidine And Trastuzumab Deruxtecan As The First-line Treatment For HER2-positive Gastric Cancer - Mayo Clinic

   ALT is normal. Remain on anti-viral therapy, per institutional practice, during the study intervention and follow-up periods to ensure adequate viral ...

4. Losartan for Outpatients on COVID-19 - Clinical Trials

   Documented AST or ALT > 3 times the upper limit of normal within 3 months of randomization (if available in electronic medical record). Potassium > 5.0 mmol ...

5. Clinical Trials - FT576 in Subjects With Multiple Myeloma

   - AST > 3 x ULN or ALT > 3 x ULN, unless directly due to underlying malignancy. - O2 sat < 92% on room air. Clinically significant cardiovascular disease ...

6. Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy - Mayo Clinic

   Aspartate aminotransferase (AST)/ alanine aminotransferase (ALT) ≤ 2.5x ULN; Alkaline Phosphatase <5x ULN. All females of childbearing potential (not ...

7. A Study Evaluating Temozolomide vs. Temozolomide and Olaparib for Advanced Pheochromocytoma and Paraganglioma - Mayo Clinic

   AST/ALT ≤ 3.0 x ULN;; Creatinine < 1.5 x ULN OR Calc. Creatinine Clearance > 50 mL/min.***. *. In the absence of transfusion within the previous 24 hours ...

8. Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma - Mayo Clinic

   Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 x ULN. Calculated creatinine clearance (CrCL) ≥ 30 mL/min. Eastern Cooperative ...

9. A Study to Evaluate the Combination of Binimetinib and Palbociclib in Treating Patients with KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer - Mayo Clinic

   Aspartate transaminase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN; ≤ 5.0 x ULN if known liver metastases;; Serum creatinine ≤ 1.5 mg/dL OR ...

10. Study to Analyze Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy - Mayo Clinic

    AST or ALT ≤ 3 x upper limit of normal (ULN). Exclusion Criteria: Any non-compliance with Inclusion Criteria above. Participating Mayo Clinic locations.